116 active trials 63 recruiting 11 Phase 3 84 sponsors 11 changes in 30 days
| Early Phase 1 | 18 | |
| Phase 1 | 28 | |
| Phase 1/2 | 18 | |
| Phase 2 | 20 | |
| Phase 3 | 11 | |
| Phase 4 | 1 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07609940 | Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of… | Regeneron Pharmaceuticals | Recruiting | 2026-08-20 |
| Phase 3 | ||||
| NCT06508983 | A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus… | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | 2026-07-10 |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Regeneron Pharmaceuticals | Recruiting | 2026-07-01 |
| NCT05730036 | A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab… | Regeneron Pharmaceuticals | Recruiting | 2026-03-06 |
| NCT06561854 | Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and… | Assistance Publique - Hôpitaux de Paris | Recruiting | 2024-12-18 |
| NCT04162210 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose… | GlaxoSmithKline | Active, Not Recruiting | 2026-07-01 |
| NCT06956170 | All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd)… | GlaxoSmithKline | Active, Not Recruiting | 2026-06-12 |
| NCT04484623 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd… | GlaxoSmithKline | Active, Not Recruiting | 2026-06-12 |
| NCT07569757 | Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not Yet Recruiting | 2026-05-08 |
| NCT06868667 | Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin… | GlaxoSmithKline | Active, Not Recruiting | 2026-04-23 |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin… | GlaxoSmithKline | Active, Not Recruiting | 2026-04-23 |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone… | GlaxoSmithKline | Active, Not Recruiting | 2026-04-23 |
| Phase 2 | ||||
| NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory… | SCRI Development Innovations, LLC | Recruiting | 2026-08-11 |
| NCT07284758 | A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With… | C4 Therapeutics, Inc. | Recruiting | 2026-08-06 |
| NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release… | Janssen Research & Development, LLC | Recruiting | 2026-07-31 |
| NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | Dr. Zaineb Akram | Recruiting | 2026-07-08 |
| NCT06421675 | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma | Ontario Clinical Oncology Group (OCOG) | Recruiting | 2026-06-17 |
| NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell… | The First Hospital of Jilin University | Recruiting | 2026-04-03 |
| NCT05896228 | Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With… | Benjamin T Diamond, MD | Recruiting | 2026-03-11 |
| NCT05530421 | Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory… | University of Miami | Recruiting | 2026-02-23 |
| NCT06711705 | Elranatamab in Relapsed/Refractory Multiple Myeloma | University of California, San Diego | Recruiting | 2026-02-20 |
| NCT05922501 | Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma | Massachusetts General Hospital | Recruiting | 2026-01-14 |
| NCT06668792 | An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With… | Biocad | Recruiting | 2025-02-04 |
| NCT06115135 | A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for… | Oncotherapeutics | Recruiting | 2025-01-16 |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of… | The First Affiliated Hospital of Xiamen University | Recruiting | 2024-09-25 |
GlaxoSmithKline (8) · Institute of Hematology & Blood Diseases Hospital, China (8) · Regeneron Pharmaceuticals (5) · AbbVie (3) · The First Affiliated Hospital with Nanjing Medical University (3) · C4 Therapeutics, Inc. (2) · Caribou Biosciences, Inc. (2) · Chongqing Precision Biotech Co., Ltd (2) · Genentech, Inc. (2) · Hangzhou Sumgen Biotech Co., Ltd. (2)